Abstract: Provided are an antigen-binding molecule specifically binding to GPRC5D and CD3, and the medical use thereof. The antigen-binding molecule can be used for treating tumor-related diseases.

Abstract: Murine, chimeric or humanized anti-Abeta antibody having a specific CDR region, an antigen-binding fragment thereof, a pharmaceutical composition thereof, and usage thereof. Use of a humanized anti-Abeta antibody for the preparation of drugs for the treatment of a disease or disorder (such as Alzheimer's disease) caused by amyloid beta protein.

Abstract: The present disclosure relates to a CD3 antibody and a pharmaceutical use thereof. Specifically, the present disclosure relates to forming a multi-specificity antibody by using CD3 antibody and binding molecules of another target. The multi-specificity antibody may simultaneously bind to CD3 and another tumor-associated antigen, and bind and activate CD3-positive T cells while binding tumor-associated antigen-expressing cells, thereby promoting T cells specifically killing tumor cells that express tumor-associated antigens. In addition, the present disclosure also provides a preparation and application of a multi-specific antibody.

Abstract: Provided are an IL-5 antibody, an antigen binding fragment thereof, and a medical application therefor. The present invention comprises a mouse-derived antibody containing an IL-5 antibody CDR region, a chimeric antibody, a humanized antibody, and a pharmaceutical composition comprising said IL-5 antibody and said antigen binding fragment thereof, as well as the use of the pharmaceutical composition as a drug.

Abstract: An anti-DLL3 antibody and a pharmaceutical use thereof, and an antibody-drug conjugate containing the anti-DLL3 antibody. The present disclosure relates to an anti-DLL3 antibody-ecteinascidin drug conjugate represented by general formula (Pc-L-D), wherein Pc is the anti-DLL3 antibody.

Abstract: Provided are an antigen-binding molecule specifically binding to PSMA and CD3, and a pharmaceutical use thereof. The antigen-binding molecule can be used for treating tumor-related diseases.

Abstract: Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a medicament for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.

Abstract: An anti-IL23 antibody fusion protein and uses thereof, the anti-IL23 antibody fusion protein containing anti IL23 antibodies and TAC polypeptides, and the IL23 antibodies specifically binding the human IL23 p19 subunit. The anti-IL23 antibody fusion protein can be used for the treatment or improvement of B cell disorders or autoimmune diseases.

Abstract: Provided is an antigen-binding molecule, particularly a domain-engineered antibody, wherein at least one constant region domain CH1/CL of the antibody is replaced by a Titin T-chain/Obscurin-O chain.

Abstract: The present invention relates to anti-PD-1 antibodies and antigen-binding fragments, and use of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.

Abstract: The present application relates to a truncated TACI polypeptide and a fusion protein and use thereof. Specifically, provided are a TACI polypeptide as shown in SEQ ID NO: 8, a truncated fragment thereof, a mutation sequence thereof, and a fusion protein comprising the TACI polypeptide and use thereof.

Abstract: The present disclosure relates to anti-KLB antibodies and uses.

Abstract: Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a medicament for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.

Abstract: The present disclosure relates to an antigen-binding molecule specifically binding to RANKL and NGF, and a medical use thereof. Specifically, provided are a novel anti-RANKL antibody, a bispecific antibody targeting RANKL and NGF, a preparation method for the antibody, and a use thereof in treatment or prevention of diseases.

Abstract: A light guide plate structure includes a body and a plurality of microstructures. The body includes a first surface, a second surface, and a light incident surface. The light incident surface is connected to the first surface and the second surface. The light incident surface faces a light source, and light incident by the light source via the light incident surface has a light source direction on the body. The microstructures are formed on the first surface and have crests and troughs along a second direction, where projections of the crests on the first surface are distributed on a plurality of first wave trajectories, each of the first wave trajectories extends along the light source direction, and the troughs have ups and downs in the first direction. The light guide plate structure may improve the optical grade of pictures of a display device. A backlight module is also provided.

Abstract: One or more computing devices, systems, and/or methods are provided. In an example, a first performance metric score may be determined based upon first content item text. A plurality of similarity scores associated with a plurality of sets of content item text may be determined. One or more sets of content item text may be selected from among the plurality of sets of content item text based upon the plurality of similarity scores and a plurality of performance metric scores associated with the plurality of sets of content item text. The plurality of performance metric scores may comprise one or more performance metric scores associated with the one or more sets of content item text. The one or more performance metric scores may be higher than the first performance metric score. One or more representations of the one or more sets of content item text may be displayed.

Abstract: One or more computing devices, systems, and/or methods are provided. In an example, a first performance metric score may be determined based upon first content item text. A plurality of similarity scores associated with a plurality of sets of content item text may be determined. One or more sets of content item text may be selected from among the plurality of sets of content item text based upon the plurality of similarity scores and a plurality of performance metric scores associated with the plurality of sets of content item text. The plurality of performance metric scores may comprise one or more performance metric scores associated with the one or more sets of content item text. The one or more performance metric scores may be higher than the first performance metric score. One or more representations of the one or more sets of content item text may be displayed.

Abstract: The present invention relates generally to antibodies in the treatment of human disease and reduction of adverse events related thereto. More specifically, the present invention relates to the use of IL 1RAP (Interleukin-1 receptor accessory protein) binding proteins (including anti-IL 1RAP 0 antagonist antibodies) and their use as treatment and prevention of human disease.

Abstract: Provided are an anti-PSMA antibody-Exatecan analogue conjugate and medical use thereof. Specifically, provided is an anti-PSMA antibody-drug conjugate represented by general formula (Pc-L-Y-D), wherein Pc is an anti-PSMA antibody or an antigen-binding fragment thereof.

Abstract: The present disclosure relates to a new polypeptide complex. Specifically, the present disclosure relates to a domain engineered antibody. At least one of the constant region domains CH1 and/or CL of the antibody is replaced, and the domain CH1/CL is replaced by a Titin T chain/Obscurin-O chain or by a Titin T chain/Obscurin-like-O chain.